Iress Limited

The Business

Iress makes core operating software for financial advisers, wealth platforms, and trading desks, split across three main divisions. Global Trading & Market Data, its trading infrastructure and market data business, contributes about half of group revenue. APAC Wealth, centred on the Xplan advice platform, generates roughly 27% and holds the dominant Australian position. UK Wealth & Superannuation, at about 21%, provides similar advice and platform technology in Britain, though Iress is a smaller player there than at home. Roughly six in ten Australian financial advisers run their practice on Xplan, a position built over two decades and reinforced by a migration process that typically takes advisers 12 to 18 months to complete.

Recent Performance

The stock has re-rated over the past year as a cost-cutting programme lifted EBITDA margin to 27.4% in the first half of FY26, up from a three-year average closer to 25%. Management delivered $31.5m of annualised savings, 105% of its original target. Revenue was essentially flat over the same period. That divergence, cost removal driving earnings while revenue stalls, is the key feature of the last twelve months, and the market has extrapolated the resulting margin forward as if it were the new baseline.

Outlook

We forecast revenue growth of roughly 2% annually over the next few years, driven almost entirely by pricing (annual escalators of around 3%) rather than volume, since the Australian adviser population has stopped growing. EBITDA margin is expected to compress from its current elevated level as capital expenditure normalises from an unusually low base toward a more typical level, and as a new development partnership adds ongoing operating costs. Earnings per share still grow over the forecast period, just more slowly than the current price appears to assume.

Key Risks

Margin compression from capex normalisation is the largest swing factor in the thesis. First-half capital expenditure ran well below the level we consider sustainable, and management has guided to a step-up in the second half; if spending fully normalises, the elevated margin the market is currently paying for would prove temporary rather than structural. A stall in organic revenue growth below current trend would remove the case for any re-rating on growth grounds, leaving Iress purely a margin story. Separately, UK goodwill sits against a division currently recording negative constant-currency growth, and a sustained failure to return that business to growth would raise impairment risk.

What to Watch

The thesis-defining event is the FY26 full-year result in February 2027, which will disclose second-half capital expenditure and confirm or refute the margin compression path.

• Feb 2027 FY26 full-year results — second-half capex disclosure will show whether spending has normalised toward historical trend or stayed structurally low.
• Aug 2027 1H27 results — first clean half-year read on post-normalisation margins.

Company Description

Iress Limited is an ASX-listed financial services software company, providing the technology infrastructure that underpins trading desks, wealth platforms, and financial advice practices across Australia, the UK and other markets. Global Trading & Market Data supplies trading infrastructure, market data feeds and a connectivity hub used by over 600 brokers, contributing about half of group revenue. APAC Wealth, centred on the Xplan advice platform, generates roughly 27% of revenue and holds the dominant position in Australian financial planning software. UK Wealth & Superannuation, at about 21% of revenue, provides similar advice and platform technology to UK-based advisers and superannuation administrators, though Iress is a smaller player in that market than at home.

Where the Growth Is

APAC Wealth is the growth engine, growing at 3.0% in constant currency terms, the fastest of the three divisions, before fading toward a 2.5% terminal rate as pricing gains normalise. The division already accounts for around 27% of group revenue. The upside case rests on AI-enabled advice modules and the shift toward scaled, lower-cost advice models following regulatory reform. This is optionality rather than base case, since module attach rates today remain low and unproven at scale.

Competitive Position

Iress holds roughly 60% of the Australian financial adviser market for practice management software, a position that has been stable rather than expanding. The advantage is structural: migrating a practice off Xplan typically takes 12 to 18 months, during which client data, workflows, and compliance processes become deeply embedded in the platform. That switching cost, combined with rising regulatory complexity around advice licensing that only a well-resourced incumbent can service cost-effectively, keeps competitors at bay. We assess this position as durable for the next five to seven years, not indefinitely: AI-native advice tools are an emerging threat, and the Australian adviser population itself has stopped growing, capping how far the moat can be monetised through volume rather than price.

Management & Capital Discipline

The cost programme is the clearest evidence of management execution to date: $31.5m in annualised savings against a $30m target, delivered through headcount reduction, office consolidation and system rationalisation, and appearing durable since it comes from structural cuts rather than one-off items. Less impressive is capital allocation beyond cost-cutting: with leverage at just 0.5 times EBITDA, the balance sheet has ample room for a buyback, yet none has been pursued. The board also explored and rejected a change-of-control process in 2025. Chief executive Andrew Russell has been in the role for under a year, too short a track record to assess strategic judgement beyond the inherited cost programme.

Financial Position

Iress carries net debt of around 0.5 times EBITDA, comfortably below covenant thresholds, with $125m of undrawn facilities and $46m of cash on hand. Debt maturity is not due until May 2029, removing near-term refinancing risk. Free cash flow conversion remains solid even as capital expenditure normalises, supporting a fully franked dividend at a 60% payout ratio. This is a balance sheet built to withstand a downturn: recurring revenue of around 95% means cash flow is unusually resilient to a cyclical slowdown, even if margin normalisation weighs on the earnings line over the next few years.